Scott+Scott Attorneys at Law LLP Alerts Investors of The Pending Class Action Against Iovance Biotherapeutics, Inc. (IOVA)

A securities class action lawsuit has been filed against Iovance Biotherapeutics (IOVA) on behalf of investors who purchased securities between May 9, 2024, and May 8, 2025. The lawsuit alleges that Iovance made misleading statements regarding the commercial launch of Amtagvi, specifically related to longer timelines for new Authorized Treatment Centers and ineffective patient identification, leading to lower revenue. This followed Iovance's May 8, 2025, announcement of disappointing Q1 2025 revenue of $49.3 million and a reduced FY25 revenue guidance, causing the stock price to fall 44.8%.

Analysis

Iovance Biotherapeutics (IOVA) is currently embroiled in a securities class action lawsuit filed on behalf of investors who acquired securities between May 9, 2024, and May 8, 2025. The lawsuit, reflecting a highly negative sentiment score of -0.7, alleges that the company and its executives made false or misleading statements and failed to disclose significant challenges related to the commercial launch of Amtagvi, its cell therapy for metastatic melanoma. Specific allegations include longer-than-anticipated timelines for new Authorized Treatment Centers (ATCs) to begin patient treatment, inefficiencies in patient identification and selection by the sales team and new ATCs leading to higher patient drop-offs, and resultant increased costs and lower revenue due to an inability for ATCs to keep pace with manufactured product. These issues culminated in the company's announcement on May 8, 2025, revealing Q1 2025 total product revenue of $49.3 million, a stark decline from the prior quarter's $73.7 million. Furthermore, Iovance significantly slashed its FY25 total product revenue guidance from a range of $450 million-$475 million down to $250 million-$300 million, citing these "recent launch dynamics" and issues with ATC growth and treatment timelines. The market reacted severely, with Iovance's stock price plummeting by $1.42 per share, or 44.8%, to close at $1.75 on May 9, 2025, indicating substantial investor concern over the commercial execution and future prospects of Amtagvi.

Key Decisions for Investors

• Investors should exercise extreme caution with Iovance Biotherapeutics due to the ongoing class action lawsuit, the significant downward revision in revenue guidance for Amtagvi, and the operational challenges highlighted in its commercial launch.
• Current shareholders should closely monitor developments in the litigation, scrutinize upcoming company communications for evidence of rectifying ATC onboarding issues and improving patient uptake, and reassess their position given the heightened risk profile.
• Potential investors should consider the substantial uncertainties surrounding Amtagvi's revenue ramp-up and the legal overhang; awaiting clear signs of operational stabilization and more predictable financial performance may be prudent before committing capital.